Study Comparing Intravenous Infusion to Subcutaneous Injection In Patients With Ulcerative Colitis
The purpose of this study is to study the effectiveness and safety of vedolizumab intravenous (by vein) infusion compared to adalimumab subcutaneous (under the skin) injection in patients with moderately to severely active ulcerative colitis (UC). Vedolizumab (also called Entyvio®) and adalimumab (also called Humira®) are approved by the U.S. Food and Drug Administration for treatment of moderately to severely active UC. We expect to enroll about 5 subjects at Rush University Medical Center. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Have physician-diagnosed UC by endoscopy or radiography for at least 6 months.
- Have moderately to severely active UC.
- Have UC that is no longer responding to the UC medications you are taking or are no longer able to take your UC medications as determined by your physician.
This is a partial list of eligibility criteria. To inquire about your eligibility, please call the contact number provided.